CAS: 1593673-23-4; Methyl (S)-3-(2-((4-Cyano-4-(3,4-Dimethoxyphenyl)-5-Methylhexyl)(Methyl)Amino)Ethyl)Benzoate

主要参考文献

1: Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E, Deeb A, Goldfaden RF. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. doi: 10.1007/s40256-023-00589-2. Epub 2023 Jun 6. Erratum in: Am J Cardiovasc Drugs. 2023 Jul 21;: 46(3):100430. doi: 10.1016/j.cpcardiol.2019.05.003. Epub 2019 Jun 22. 29(1):1-4. doi: 10.1080/13543784.2020.1703180. Epub 2019 Dec 12. 15(1):2-6. doi: 10.17925/HI.2021.15.1.2.
5: Faisaluddin M, Ashish K, Hajra A, Mondal S, Bandyopadhyay D. Etripamil: Self- management of supraventricular tachycardia is not far away? Int J Cardiol Heart Vasc. 2019 Jan 4;22:82-83. doi: 10.1016/j.ijcha.2018.12.007.
6: Weintraub S, Frishman WH. A Novel Calcium Channel Blocker: Etripamil: What is the Future of Intranasal Drug Delivery in the Treatment of Cardiac Arrhythmias? Cardiol Rev. 2021 Sep-Oct 01;29(5):253-258. doi: 10.1097/CRD.0000000000000362. 12(19):e028227. doi: 10.1161/JAHA.122.028227. Epub 2023 Sep 27. 72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. 23(6):735-736. doi: 10.1007/s40256-023-00595-4. Erratum for: Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. RAPID Investigators. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023 Jul 8;402(10396):118-128. doi: 10.1016/S0140-6736(23)00776-6. Epub 2023 Jun 15. 15(12):e010915. doi: 10.1161/CIRCEP.122.010915. Epub 2022 Nov 28.

合成参考文献

摘要:https://milestonepharma.com/etripamilprescribinginformation.pdf